Multifactorial Intervention in Type 2 Diabetes - Italy
Multifactorial Intervention in Type 2 Diabetes - Italy
Despite several clinical trials have clearly demonstrated that the correction of a single
 cardiovascular risk factor in patients with type 2 diabetes decreases the incidence of
 myocardial infarction and other cardiovascular disease (CVD) events, only the Steno study has
 been evaluating the effect of a multifactorial intervention strategy on macrovascular
 complications of diabetes. For this reason, the disease management approach currently
 endorsed by international guidelines (i.e correction of all major CVD risk factors to target
 levels usually lower than lower risk populations) has not been extensively investigated in
 terms of prevalence of application in current clinical practice and in terms of real
 efficacy.

 The Multifactorial INtervention in type 2 Diabetes - ITaly (MIND.IT) is a multicentric
 two-phase study involving 9 Diabetes Care Units throughout Italy with the overall aims of:
 (1) investigating the degree of application of the international guidelines for CVD
 prevention in type 2 diabetic patients and (2) verifying whether the application of an
 intensive multi-factorial intervention inspired by these guidelines is feasible and effective
 in decreasing the incidence of new CVD events.
The study is multi-centric, randomized, open label, active treatment controlled, two
 parallel-group, pragmatical intervention trial with 5 years of follow-up, to assess
 superiority of an intensive treat-to-target strategy (including lifestyle and pharmacological
 interventions) for correction of major cardiovascular risk factors compared to usual care in
 decreasing incidence of first cardiovascular events in non complicated type 2 diabetic
 patients at high risk, as defined by presence of 2 or more cardiovascular risk factors. All
 high-risk patients identified during phase 1 who accepted to participated were allocated to
 usual or intensive treatment based on the recruiting center. Centers were randomly assigned
 to treatment arm before phase 2 beginning. Investigators from Intensive Care centers received
 centralized training to ensure the application of the intensive care program on their
 patients.

 HbA1c values and lipid profile are assessed in peripheral laboratories (one per each study
 site) with an external, centralized, quality control program and the adjustment for
 systematic differences among study labs.

 Participating investigators are left free to decide upon patient's treatments. In
 intensive-care centers, investigators are provided with a multi-factorial step-wise protocol
 to support the application of a treat-to-target approach. Intensive care strategy includes
 intervention on lifestyle.

 Dietary intervention goals: BMI<25 or 5% reduction of body weight; dietary assumption of
 saturated fat <10% of total caloric intake; fibers= 15-20 g/1000 Kcal. Methods defined to
 reach the dietary goal: A) Patients with BMI 25-30 kg/m2: reduction of caloric intake =
 300-500 Cal/d; B) Patients with BMI >30: reduction of caloric intake 500-800 Cal/d.

 Physical activity intervention goal: 200-300 calories per day. Example: brisk walking for 30
 min every day or biking (18-25Km/h 45-60 min). Alternatives: swimming 1h , dancing 1h, gym
 exercise 1h;-avoiding isometric exercise and exercise with intensity >50-60 % of maximal
 oxygen consumption. Frequency: everyday or at least 3 times a week; Pharmacological
 intervention: Blood glucose control, multi-step intervention. In obese patients: 1) Metformin
 (M, 500-2500mg); 2) M+Sulphonylureas (S) or S-like drugs, increasing progressively the dose;
 3) M+S+Acarbose; 4) M+S+insulin bed-time; 5) insulin basal-bolus. In normal weight patients:
 1) S; 2) S+acarbose; 3) S+ bed-time insulin; 4) insulin basal bolus; Blood pressure control
 --> 1) Ace-inhibitors or AT-II receptor antagonists; 2) add long acting calcium-channel
 blockers or beta-blockers or low dose diuretics; 3) add a third drug; lipid control: 1) diet
 + physical activity; 2) if LDL > 130 mg/dL statins (with a stepwise increase of dose if
 necessary); if triglycerides > 200 mg/dL fibrates; anti-platelet treatment: aspirin 100 mg/d
 in all patients (alternative drugs for aspirin-intolerants).

 The scheduled visits were defined as follows:

 -  Intensive-care group: mandatory visit every three months with annual visit for MIND.IT
 data collection.

 -  Usual-care group: at least one MIND.IT visit every year + the usual organization of the
 center.
Inclusion Criteria:

 -  Both genders

 -  age 50-70 years

 -  Type two diabetes with at least two-year history of disease and without insulin
 treatment in the first two years after diagnosis

 -  Negative medical history for documented previous cardiovascular events or
 macrovascular complications

 -  Written consent to participate

 -  Presence of at least 2 of the following risk factors:

 -  LDL cholesterol > 130 mg/dL (regardless of treatment)

 -  Triglycerides > 200 mg/dL

 -  HDL cholesterol < 35 (males) or 45 (females) mg/dL

 -  Blood pressure > 140/90 mmHg

 -  Cigarette smoking

 Exclusion Criteria:

 -  Age below 50 or above 70 years

 -  Type 1 diabetes, diagnosis before 40 years of age, known presence of auto-antibodies
 or insulin requirement in the first 2 years of disease.

 -  Chronic kidney failure (plasma creatinine > 2 mg/dL)

 -  Significant liver damage (AST and/or ALT > 2 times the upper limits of normality)

 -  History of previous cardiovascular events

 -  Active neoplasms or any concomitant disease limiting life expectancy